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SUMMARY · Presentation is made of a 41-year-old man with Addison’s disease and coexistent
Hashimoto’s thyroiditis and hypothyroidism. The two diseases are presumed to be of autoimmune
etiology and to manifest as part of the autoimmune polyglandular syndrome type II, as also sug-
gested by tissue typing for HLA B8 locus. Inadequate TSH suppression with standard levothyroxine
substitution therapy for a one-year period or with higher substitution doses of 200 mg during TRH
stimulation, with FT4 which showed no major increase but remained within lower normal limits,
indicated partial hypophyseal resistance to thyroxin and/or possible development of autoantibodies
to peripheral thyroid hormones.
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Introduction
Lymphocytic infiltration of the adrenal cortex and
thyroid gland was for the first time detected in 1926 by
Schmidt’s excisional biopsy in a patient who died from
adrenal insufficiency. The condition was named Schmidt’s
syndrome. Later on, involvement of other endocrine
glands was also observed, and the syndrome was termed
autoimmune polyglandular syndrome type I and type II.
Type I includes hypoparathyroidism, mucocutaneous can-
didiasis, adrenal insufficiency, chronic active hepatitis,
malabsorption, primary hypogonadism,vitiligo, pernicious
anemia, alopecia, and primary hypothyroidism. Type I is
characterized by no HLA system and chromosome 6
compatibility, onset in childhood or adolescence, high
prevalence of mucocutaneous candidiasis, and autosomal
recessive inheritance. Type II is characterized by vertical
transmission through many generations, HLA B8 and
DR3 compatibility, chromosome 6 inheritance, onset be-
tween age 20 and 60, absence of mucocutaneous candidi-
asis, and autosomal dominant inheritance. Rodriguez
Quiroz et al.1 have recently reported on a patient with
autoimmune polyglandular syndrome type III, and de-
fined the state as coexistence of insulin dependent diabe-
tes mellitus, hyper- or hypothyroidism and no other en-
docrine disease, with or without rheumatic disease. Less
common manifestations of the syndrome include perni-
cious anemia, vitiligo and alopecia. Cellular and humoral
immunity disorders are present in most autoimmune dis-
eases. The immune system recognizes its own antigens
and does not react to them. The principle is established
during fetal life and continues after birth. There are vari-
ous theories on the occurrence of autoimmune reaction,
e.g., abnormal antigen expression, primary hormono-
genesis defect, clone theory, and abnormal immune ho-
meostasis as the most important theory.
Thyroid hormone antibodies are known since 1956,
when Robbins et al.3 described specific gamma globulin
thyroxine carriers in a case of papillary carcinoma of the
thyroid. In 1967, Premancharda and Blumenthal4 dem-
onstrated thyroid gland antibodies in six of 15 patients
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with Hashimoto’s thyroiditis. T3 and T4 antibodies have
been found in many thyroid diseases, manifesting as a
changed level of thyroid hormones. However, these anti-
bodies have no effect on the peripheral level of thyroid
hormones if thyroid reserve on TRH stimulation is nor-
mal.
There may be a thyroid hormone blocking mechanism
on the receptors that suppress endogenous TSH secretion.
There may also be antibodies that bind circulating thy-
roid hormones and inhibit the effect on hypophysis and/
or render it unavailable for analysis. TSH hypersecretion
is the most common physiological sequel of decreased le-
vels of free thyroid hormones. It can rarely be consequen-
tial to hypophyseal cell TSH secreting adenoma or hypo-
thalamic cell TRH secreting adenoma. It may also occur
in the form of pituitary generalized or partial resistance,
along with thyroid tissue resistance, its most severe mani-
festation being struma with cretinism or juvenile hypoth-
yroidism. Another form is selective resistance (partial
hypophyseal resistance to hypophyseal peripheral hor-
mones without tissue resistance), which is manifested by
the clinical picture of hypermetabolism. It is believed that
T3 and T4 hormones have multiple cellular effects with
nuclear hormone receptors (TR alpha, TR beta). Thyroid
hormone resistance is caused by TR beta gene mutation8.
Case Report
B. M., a 41-year-old man, underwent appendectomy.
A week later, he became adynamic, prostrate, hypotensive,
with hyperkalemia and hyponatremia. Addison’s disease
was suspected for dominant skin hyperpigmentation, and
verified by hormone testing. The patient was administered
corticosteroid and mineralosteroid adjuvant therapy,
whereafter he felt well and had satisfactory hormonal and
other laboratory test results.
Ten years later, weakness, exhaustion, and physical
effort intolerance developed despite appropriate substitu-
tion therapy. Hormonal tests showed low peripheral thy-
roid hormone levels and significantly elevated TSH level,
suggesting primary hypothyroidism as part of chronic
lymphocytic thyroidism, which was confirmed by biopsy
pathohistology. The level of testosterone was lower than
expected for the patient’s age, and no other abnormalities
were found. Upon adjuvant substitution levothyroxine
therapy, suppression of TSH secretion proved refractory
to long-term standard dose or short-term hormone dose
increase.
Laboratory tests performed during the patient’s hos-
pital stay yielded the following results: cortisol at 8 a.m.
74.5 nmol/L and at 4 p.m. 27.6 nmol/L; ACTH 160
pmol/L; 24-h urine 17-CS 1 mg; 24-h urine 17-OHCS
0.6 mg; 8-h stimulation with 25 U ACTH showed no
suppression; serum aldosterone <191.3 pmol/L; 24-h
urine <11.82 mmol/L; serum renin >8.00 pg/ml; T3 0.9
nmol/L;T4 33.6 nmol/L; TSH >80 mIU/L. Highly posi-
tive microsomal autoantibodies and thyroid biopsy cytol-
ogy indicated chronic Hashimoto’s thyroidism. TRH test
basal: TSH 0 min 47.6; 30 min 53.6; FT4 11.6 pmol/L;
levothyroxine 100 mg: TSH 0 min 24.5; 30 min 48.2; FT
4 12.9; levothyroxine 150 mg: TSH 0 min 13.9; 30 min
46.8; FT 4 12.9; parathormone <20 pg/ml; Ca and P ho-
meostasis normal. Chest and abdominal x-ray and CT
scan of the hypophysis were normal. Immunologic status:
LE cell, Walter Rose and Latex, and total complement
tests were negative; C3 0.63 g/L; C4 0.21 g/L; ANF nega-
tive; circulating immunocomplex 3.8 mg/mill; lymphocyte
markers (% of total lymphocyte count) CD4/T4/helper
59.7; CD8/T8/suppressor 13.0; CD20/B1 10.1; T4/T8
4.59, elevated as the result of low T8/CD8 level. HLA
system antigens: locus HLA-A 1 26; locus HLA-B 8 12;
total protein 75 g/L; protein immunoelectrophoresis nor-
mal; IgG 11.9; IgA 2.21; IgM 0.64.
Discussion
In our patient, the diagnosis of Addison’s disease was
verified by laboratory (hormone) testing, which showed
high serum ACTH, low serum cortisol, and low 24-h uri-
ne cortisol levels. Serum and urinary aldosterone showed
decreased values, while renin was elevated, indicating
mineralocorticoid insufficiency of primary hypocorticism.
Pathohistology revealed significantly positive microsomal
antibodies, pointing to Hashimoto’s thyroiditis. Low thy-
roid peripheral hormones and significantly elevated TSH
levels confirmed the diagnosis of primary hypothyroidism.
The patient received one-year substitution  therapy with
100 mg levothyroxine without TSH suppression for par-
tial hypohyseal resistance to peripheral thyroid hormones.
The patient was admitted to the hospital, underwent
TRH stimulation test, and was prescribed progressively
rising levothyroxine dosage up to 200 mg/L for coexist-
ent Addison’s disease refractory to the high dose of the
drug. However, increased TSH levels persisted, along with
positive stimulation test, while free FT4 remained within
the lower normal limits. It was presumed, therefore, that
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in spite of partial thyroxine thyrotropic resistance, autoan-
tibodies to thyroid hormones may have existed, as sug-
gested by unchanged FT4 levels in spite of the high
levothyroxine dosage. CT scan excluded TSH adenoma
and tuberculotic etiology of Addison’s disease. The two
diseases could be considered as part of the autoimmune
polyglandular syndrome type II, as also indicated by the
HLA B8 locus.
The pathogenesis of autoimmune polyglandular syn-
drome remains obscure. The medications used for immu-
nosuppression still have serious side effects. The concept
of the locus HLA B8 and HLA DR3 related syndrome
appears to be quite intriguing. Early detection of the dis-
ease allows for significant morbidity and mortality reduc-
tion in patients with autoimmune polyglandular syn-
drome. Family members and kindred should be screened
annually. Many syndrome diseases can be treated with
respective substitution therapy. However, most authors
consider that in the future, immunologic therapy should
be focused on immunomodulation rather than immuno-
suppression.
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Saæetak
AUTOIMUNI POLIGLANDULARNI SINDROM TIP II. · PRIKAZ SLU»AJA
B. BeËejac, M. BekiÊ, M. Misjak, M. Solter i M. Vrkljan
Prikazan je 41-godi¹nji bolesnik s Addisonovom bole¹Êu i pridruæenim Hashimotovim tireoiditisom i hipotireozom. Za
pretpostaviti je da su ove dvije bolesti autoimune etiologije i da se javljaju u okviru autoimunog poliglandularnog sindroma
tipa II., na ¹to upuÊuje i tipizacija tkiva u smislu HLA B8 lokusa. Nedovoljna supresija TSH standardnom nadomjestnom
terapijom  levotiroksinom kroz dulje vremensko razdoblje od godinu dana, kao i veÊim nadomjestnim dozama od 200 mg
tijekom stimulacije TRH, uz FT4 koji se nije znaËajnije povisio, nego je ostao u niæem normalnom rasponu, ukazivala je na
djelomiËnu rezistenciju hipofize na tiroksin i/ili moguÊnost razvoja autoantitijela na periferne hormone ¹titnjaËe.
KljuËne rijeËi: Poliendokrinopatije, autoimune, dijagnostika; Addisonova bolest, etilogija; Tiroiditis, automuni, dijagnostika; Prikaz
sluËaja
